Aldevron - What We Do

Aldevron - Who We Are v2

Aldevron - Who We Are v1

Discover the Power of Small and Safe with Nanoplasmid®

GEN Webinar: The Future of CRISPR Cell Therapies is GMP

CRISPR-Associated Nucleases for Gene Editing | Max Sellman

Manufacturing CRISPR RNPs for Clinical Applications | Shawn Shafer, Ph.D.

Learn how the RNA-OUT antibiotic-free selection system works in the Nanoplasmid® vector

Manufacturing CRISPR RNPs for Clinical Applications

Manufacturing CRISPR RNPs for Clinical Applications

Nanoplasmid® —the next-generation plasmid vector

Aldevron @ Meeting on the Mesa, October 2022

Aldevron @ Biotech Week Boston: Cas9 Enzymes and Nanoplasmid®: Superior Tools for Gene Editing

Roles, Responsibilities, & Project Management Concerns | James Brown, Ph.D.

Webinar: Standardization and Large-scale Manufacturing of Plasmids for Viral Vector Production

Aldevron's mRNA Capabilities | Nate Spangler, Ph.D.

CRISPR-Associated Nucleases for Gene Editing | Max Sellman

Manufacturing Considerations for Successful Gene Therapy Development | Tanner Dockendorf

Aldevron CRISPR Products, Services, and Capabilities | Tom Foti

Advancing Therapies with mRNA

CRISPR-Associated Nucleases for Gene Editing | Max Sellman

Plasmid DNA Insights: Expanded Focus on CMC in Gene & Cell Therapy Development

Supply Chain for Gene Modified Cell Manufacturing | Tom Foti

GEN Webinar: Genome Editing Tools: Beyond Discovery

How a Sponsored CMC Platform Accelerates mRNA Projects into the Clinic

Self-amplifying and messenger RNA for Vaccines and Therapies: Manufacturing for clinical stages

OPCU: Outsourced Pharma Capacity Update, Featuring Todd Howren

Aldevron - Advancing Every Day

Jennifer Meade, Aldevron President

Badger Challenge: Pie Your Manager Fundraiser